scholarly journals Stem cell biology and regenerative medicine for neonatal lung diseases

2017 ◽  
Vol 83 (1-2) ◽  
pp. 291-297 ◽  
Author(s):  
Martin Kang ◽  
Bernard Thébaud
Keyword(s):  
Stem Cell ◽  
Regenerative Medicine ◽  
Cell Biology ◽  
Lung Diseases ◽  
Stem Cell Biology ◽  
Neonatal Lung

Realistic Prospects for Stem Cell Therapeutics

Hematology ◽  
2003 ◽  
Vol 2003 (1) ◽  
pp. 398-418 ◽  
Author(s):  
George Q. Daley ◽  
Margaret A. Goodell ◽  
Evan Y. Snyder
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Regenerative Medicine ◽  
Cell Biology ◽  
Adult Stem Cells ◽  
Stem Cell Biology ◽  
Cell Therapies ◽  
The Media ◽  
New Treatment ◽  
Definition Of

Abstract Studies of the regenerating hematopoietic system have led to the definition of many of the fundamental principles of stem cell biology. Therapies based on a range of tissue stem cells have been widely touted as a new treatment modality, presaging an emerging new specialty called regenerative medicine that promises to harness stem cells from embryonic and somatic sources to provide replacement cell therapies for genetic, malignant, and degenerative conditions. Insights borne from stem cell biology also portend development of protein and small molecule therapeutics that act on endogenous stem cells to promote repair and regeneration. Much of the newfound enthusiasm for regenerative medicine stems from the hope that advances in the laboratory will be followed soon thereafter by breakthrough treatments in the clinic. But how does one sort through the hype to judge the true promise? Are stem cell biologists and the media building expectations that cannot be met? Which diseases can be treated, and when can we expect success? In this review, we outline the realms of investigation that are capturing the most attention, and consider the current state of scientific understanding and controversy regarding the properties of embryonic and somatic (adult) stem cells. Our objective is to provide a framework for appreciating the promise while at the same time understanding the challenges behind translating fundamental stem cell biology into novel clinical therapies.

scholarly journals Multiparametric Phenotypic Screening System for Profiling Bioactive Compounds Using Human Fetal Hippocampal Neural Stem/Progenitor Cells

2015 ◽  
Vol 20 (9) ◽  
pp. 1074-1083 ◽  
Author(s):  
Yoshikuni Tabata ◽  
Norio Murai ◽  
Takeo Sasaki ◽  
Sachie Taniguchi ◽  
Shuichi Suzuki ◽  
...  
Keyword(s):  
Stem Cell ◽  
Regenerative Medicine ◽  
Progenitor Cells ◽  
Cell Fate ◽  
Bioactive Compounds ◽  
Cell Biology ◽  
Stem Cell Biology ◽  
Screening System ◽  
Human Stem Cells ◽  
Neural Stem Progenitor Cells

Stem cell research has been progressing rapidly, contributing to regenerative biology and regenerative medicine. In this field, small-molecule compounds affecting stem cell proliferation/differentiation have been explored to understand stem cell biology and support regenerative medicine. In this study, we established a multiparametric screening system to detect bioactive compounds affecting the cell fate of human neural stem/progenitor cells (NSCs/NPCs), using human fetal hippocampal NSCs/NPCs, HIP-009 cells. We examined effects of 410 compounds, which were collected based on mechanisms of action (MOAs) and chemotypes, on HIP-009’s cell fate (self-renewal, neuronal and astrocytic differentiation) and morphology by automated multiparametric assays and profiled induced cellular phenotypes. We found that this screening classified compounds with the same MOAs into subgroups according to additional pharmacological effects (e.g., mammalian target of rapamycin complex 1 [mTORC1] inhibitors and mTORC1/mTORC2 dual inhibitors among mTOR inhibitors). Moreover, it identified compounds that have off-target effects under matrix analyses of MOAs and structure similarities (e.g., neurotropic effects of amitriptyline among tri- and tetracyclic compounds). Therefore, this automated, medium-throughput and multiparametric screening system is useful for finding compounds that affect the cell fate of human NSCs/NPCs for supporting regenerative medicine and to fingerprint compounds based on human stem cells’ multipotency, leading to understanding of stem cell biology.

FEATURES

2011 ◽  
Vol 15 (07) ◽  
pp. 15-28 ◽  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Drug Discovery ◽  
Regenerative Medicine ◽  
Clinical Application ◽  
Pluripotent Stem Cells ◽  
Cell Biology ◽  
Stem Cell Biology ◽  
Differentiated Products ◽  
Safety Testing

The clinical application of stem cells in hematopoietic disease. Use of pluripotent stem cells and their differentiated products in pharmacological drug discovery and safety testing. Messages from the nucleus: Insights into Aging. inStem: The Institute for Stem Cell Biology and Regenerative Medicine.

scholarly journals Future perspective of induced pluripotent stem cells for diagnosis, drug screening and treatment of human diseases

2010 ◽  
Vol 104 (07) ◽  
pp. 39-44 ◽  
Author(s):  
Qizhou Lian ◽  
Yenyen Chow ◽  
Miguel Esteban ◽  
Duanqing Pei ◽  
Hung-Fat Tse
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Regenerative Medicine ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Cell Biology ◽  
Stem Cell Biology ◽  
Ips Cell ◽  
Cell Technology ◽  
Induced Pluripotent

SummaryRecent advances in stem cell biology have transformed the understanding of cell physiology and developmental biology such that it can now play a more prominent role in the clinical application of stem cell and regenerative medicine. Success in the generation of human induced pluripotent stem cells (iPS) as well as related emerging technology on the iPS platform provide great promise in the development of regenerative medicine. Human iPS cells show almost identical properties to human embryonic stem cells (ESC) in pluripotency, but avoid many of their limitations of use. In addition, investigations into reprogramming of somatic cells to pluripotent stem cells facilitate a deeper understanding of human stem cell biology. The iPS cell technology has offered a unique platform for studying the pathogenesis of human disease, pharmacological and toxicological testing, and cell-based therapy. Nevertheless, significant challenges remain to be overcome before the promise of human iPS cell technology can be realised.

Sign in / Sign up

Export Citation Format

Share Document